The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice

Kidney International

Volumn 82, Issue 2, 2012, Pages 158-171

  Nakagawa, Naoki ^a   Yuhki, Koh Ichi ^a,b   Kawabe, Jun Ichi ^a   Fujino, Takayuki ^a   Takahata, Osamu ^a   Kabara, Maki ^a   Abe, Kazutoshi ^a   Kojima, Fumiaki ^a,b   Kashiwagi, Hitoshi ^a,b   Hasebe, Naoyuki ^a   Kikuchi, Kenjiro ^a   Sugimoto, Yukihiko ^c   Narumiya, Shuh ^b,d   Ushikubi, Fumitaka ^a,b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

chronic kidney disease; prostaglandins; renal fibrosis

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; ONO AE 1329; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RANTES; RIVENPROST; UNCLASSIFIED DRUG; CCL2 PROTEIN, MOUSE; CCL5 PROTEIN, MOUSE; CONNECTIVE TISSUE GROWTH FACTOR; CTGF PROTEIN, MOUSE; FOLIC ACID; HEPTANOIC ACID DERIVATIVE; PTGER4 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; DRUG EFFICACY; IMMUNOREACTIVITY; KIDNEY FIBROSIS; KIDNEY TUBULE EPITHELIUM; MACROPHAGE; MOUSE; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RENAL PROTECTION; TUBULOINTERSTITIAL FIBROSIS; UPREGULATION; 129 MOUSE; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; EPITHELIUM CELL; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY DISEASE; KIDNEY TUBULE; METABOLISM; MOUSE MUTANT; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; URETER OBSTRUCTION;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CCL5; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FIBROSIS; FOLIC ACID; GENE EXPRESSION REGULATION; HEPTANOATES; KIDNEY DISEASES; KIDNEY TUBULES; MACROPHAGES; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOFIBROBLASTS; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; URETERAL OBSTRUCTION;

EID: 84863301986     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.115     Document Type: Article

References (58)

1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340.
2. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21: 1819-1834.
3. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637.
4. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-748.
5. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-529.
6. Anders HJ, Vielhauer V, Frink M et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002; 109: 251-259.
7. Anders HJ, Vielhauer V, Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003; 63: 401-415.
8. Bascands JL, Schanstra JP. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int 2005; 68: 925-937.
9. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
10. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-b pathway. Kidney Int 2006; 70: 1914-1919.
11. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784.
12. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
13. Iwano M, Plieth D, Danoff TM et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-350.
14. Humphreys BD, Lin SL, Kobayashi A et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
15. Sato M, Muragaki Y, Saika S et al. Targeted disruption of TGF-b1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486-1494.
16. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009; 75: 1145-1152.
17. Whinnery MA, Shaw JO, Beck N. Thromboxane B2 and prostaglandin E2 in the rat kidney with unilateral ureteral obstruction. Am J Physiol 1982; 242: F220-F225.
18. Okegawa T, Jonas PE, Deschryver K et al. Metabolic and cellular alterations underlying the exaggerated renal prostaglandin and thromboxane synthesis in ureter obstruction in rabbits. inflammatory response involving fibroblasts and mononuclear cells. J Clin Invest 1983; 71: 81-90.
19. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.
20. Fujino H, West KA, Regan JW. Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem 2002; 277: 2614-2619.
21. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003; 74: 143-153.
22. Bani-Hani AH, Campbell MT, Meldrum DR et al. Cytokines in epithelialmesenchymal transition: a new insight into obstructive nephropathy. J Urol 2008; 180: 461-468.
23. Misseri R, Rink RC, Meldrum DR et al. Inflammatory mediators and growth factors in obstructive renal injury. J Surg Res 2004; 119: 149-159.
24. Carlsen I, Donohue KE, Jensen AM et al. Increased cyclooxygenase-2 expression and prostaglandin E2 production in pressurized renal medullary interstitial cells. Am J Physiol Regul Integr Comp Physiol 2010; 299: R823-R831.
25. Norregaard R, Jensen BL, Topcu SO et al. Urinary tract obstruction induces transient accumulation of COX-2-derived prostanoids in kidney tissue. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1017-R1025.
26. Sugimoto Y, Namba T, Shigemoto R et al. Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney. Am J Physiol 1994; 266: F823-F828.
27. Schreiner GF, Harris KPG, Purkerson ML et al. Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney. Kidney Int 1988; 34: 487-493.
28. Burns WC, Twigg SM, Forbes JM et al. Connective tissue growth factor plays an important role in advance glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006; 17: 2484-2494.
29. Benndorf RA, Krebs C, Hirsch-Hoffmann B et al. Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. Kidney Int 2009; 75: 1039-1049.
30. Quaggin SE, Kapus A. Scar wars: mapping the fate of epithelialmesenchymal-myofibroblast transition. Kidney Int 2011; 80: 41-50.
31. Zhang AH, Wang MH, Dong Z et al. Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. Am J Physiol Renal Physiol 2006; 291: F1323-F1331.
32. Takayama K, Garcia-Cardena G, Sukhova GK et al. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002; 277: 44147-44154.
33. Takayama K, Sukhova GK, Chin MT et al. A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ Res 2006; 98: 499-504.
34. Shinomiya S, Naraba H, Ueno A et al. Regulation of TNFa and interleukin-10 production by prostaglandins I2 and E2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol 2001; 61: 1153-1160.
35. Korn JH, Halushka PV, Leroy EC. Mononuclear cell modulation of connective tissue function: suppression of fibroblast growth by stimulation of endogenous prostaglandin production. J Clin Invest 1980; 65: 543-554.
36. Lama V, Moore BB, Christensen P et al. Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol 2002; 27: 752-758.
37. Kolodsick JE, Peters-Golden M, Larios J et al. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 2003; 29: 537-544.
38. Liu F, Mih JD, Shea BS et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 2010; 190: 693-706.
39. Fine A, Poliks CF, Donahue LP et al. The differential effect of prostaglandin E2 on transforming growth factor-beta and insulin-induced collagen formation in lung fibroblasts. J Biol Chem 1989; 264: 16988-16991.
40. Clark JG, Kostal KM, Marino BA. Modulation of collagen production following bleomycin-induced pulmonary fibrosis in hamsters. Presence of a factor in lung that increases fibroblast prostaglandin E2 and cAMP and suppresses fibroblast proliferation and collagen production. J Biol Chem 1982; 257: 8098-8105.
41. Sakata D, Yao C, Narumiya S. Prostaglandin E2, an immunoactivator. J Pharmacol Sci 2010; 112: 1-5.
42. Yao C, Sakata D, Esaki Y et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat Med 2009; 15: 633-640.
43. Miyajima A, Ito K, Asano T et al. Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction? J Urol 2001; 166: 1124-1129.
44. Therland KL, Stubbe J, Thiesson HC et al. Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin E2 EP4 receptors. J Am Soc Nephrol 2004; 15: 1189-1198.
45. Paradis P, Dali-Youcef N, Paradis FW et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000; 97: 931-936.
46. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 2000; 161: 1999-2004.
47. Satoh M, Kashihara N, Yamasaki Y et al. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2001; 12: 317-325.
48. Hisada Y, Sugaya T, Yamanouchi M et al. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 1999; 103: 627-635.
49. Schanstra JP, Neau E, Drogoz P et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002; 110: 371-379.
50. Segi E, Sugimoto Y, Yamasaki A et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998; 246: 7-12.
51. Fujino T, Nakagawa N, Yuhki K et al. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest 2004; 114: 805-812.
52. Yoshida K, Oida H, Kobayashi T et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci USA 2002; 99: 4580-4585.
53. Xiao CY, Yuhki K, Hara A et al. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 2004; 109: 2462-2468.
54. Maruyama T, Kuwabe SI, Kawanaka Y et al. Design and synthesis of a selective EP4-receptor agonist. Part 4: practical synthesis and biological evaluation of a novel highly selective EP4-receptor agonist. Bioorg Med Chem 2002; 10: 2103-2110.
55. Favreau F, Zhu XY, Krier JD et al. Revascularization of swine renal artery stenosis improves renal function but not the changes in vascular structure. Kidney Int 2010; 78: 1110-1118.
56. Suzawa T, Miyaura C, Inada M et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000; 141: 1554-1559.
57. Nagatoya K, Moriyama T, Kawada N et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61: 1684-1695.
58. Eddy AA, LóRpez-Guisa JM, Okamura DM et al. Investigating mechanisms of chronic kidney disease in mouse models. Pediatr Nephrol 2011; e-pub ahead of print.